Evaxion Biotech (EVAX) said Thursday it has dosed the first patient in the one-year extension of the phase 2 trial of its personalized cancer vaccine EVX-01.

The extension further evaluates the potential of the vaccine as a potential treatment for advanced melanoma, or skin cancer, particularly its long-term clinical and immune benefits, the company said.

In the first two years of the trial, the vaccine was administered in combination with standard anti-PD-1 therapy. Patients entering the extension will receive two additional EVX-1 doses as monotherapy, and results could position the vaccine as a potential standalone treatment for the disease, Evaxion said.

The trial remains on track to yield two-year data to be presented in H2, the company said.

Evaxion Biotech shares were 3.5% higher in premarket trading.